ADP-A2M4CD8 Maintains its Efficacy in MAGE-A4+ Solid Tumors; BNT211 Continues to Impress in Solid Tumors; IM96 Demonstrates Excellent Safety Profile but Modest Preliminary Efficacy in mCRC; ESMO 2023 Analysis 2
ESMO 2023 Analysis 2: Adaptimmune, BioNTech, and Immunochina presented clinical updates from their CAR-T programs in solid tumors. Below, Celltelligence provides insights and context on key selected presentations:
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.